trending Market Intelligence /marketintelligence/en/news-insights/trending/nDrxLgjXd-uOWffzOcrWBQ2 content esgSubNav
In This List

US FDA rejects Amphastar application for asthma inhaler

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA rejects Amphastar application for asthma inhaler

The U.S. FDA withheld approval of Amphastar Pharmaceuticals Inc.'s over-the-counter asthma inhaler, Primatene Mist.

The regulator, in a complete response letter, asked the pharmaceutical company to make further changes to the inhaler's label and packaging followed by a study to evaluate patients' ability to use the product without professional guidance.

Amphastar plans to address these concerns by mid-2017.

The original Primatene Mist was discontinued because it contained chlorofluorocarbons, which are harmful to the ozone layer. The new version of the inhaler uses the same active ingredient as the old one but uses a different delivery system.